Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection



Status:Completed
Conditions:Infectious Disease, Hepatitis, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:3 - 17
Updated:9/28/2018
Start Date:July 7, 2014
End Date:September 13, 2018

Use our guide to learn which trials are right for you!

A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

This study will have two parts as follows:

The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and
confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric
participants. The PK Lead-in Phase will also evaluate the safety and tolerability of 7 days
of dosing of SOF+ribavirin (RBV) in HCV-infected pediatric participants.

The Treatment Phase will be initiated by age cohort after confirmation of age-appropriate SOF
dosage levels. Participants from the PK Lead-in Phase will immediately rollover into the
Treatment Phase with no interruption of study drug administration. The Treatment Phase will
evaluate the antiviral efficacy, safety, and tolerability of SOF+RBV for 12 or 24 weeks in
pediatric participants with genotype 2 or 3 HCV infection, respectively.


Key Inclusion Criteria:

- Consent of parent or legal guardian required

- Chronic HCV infection genotype 2 or 3

- Screening laboratory values within defined thresholds

- PK Lead-in only: all individuals must be treatment naive

Key Exclusion Criteria:

- History of clinically significant illness or any other medical disorder that may
interfere with subject treatment, assessment or compliance with the protocol

- Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus

- Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)

- Pregnant or nursing females

- Known hypersensitivity to study medication

- Use of any prohibited concomitant medications as within 28 days of the Day 1 visit

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
17
sites
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
1660
mi
from 98109
Fort Worth, TX
Click here to add this to my saved trials
2450
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
2161
mi
from 98109
Morgantown, WV
Click here to add this to my saved trials
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
7755
mi
from 98109
Westmead,
Click here to add this to my saved trials